IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study von Papp, Kim A, Weinberg, Mark A, Morris, Alun, Reich, Kristian

Volltext

Dupilumab: A review of its use in the treatment of atopic dermatitis von Gooderham, Melinda J., Hong, H. Chih-ho, Eshtiaghi, Panteha, Papp, Kim A.

Volltext

Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2) von Crowley, Jeffrey, MD, Thaçi, Diamant, MD, Joly, Pascal, MD, Peris, Ketty, MD, Papp, Kim A., MD, PhD, Goncalves, Joana, MD, Day, Robert M., PhD, Chen, Rongdean, PhD, Shah, Kamal, MD, Ferrándiz, Carlos, MD, Cather, Jennifer C., MD

Volltext

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis:... von Blauvelt, Andrew, MD, MBA, Papp, Kim A., MD, PhD, Griffiths, Christopher E.M., MD, Randazzo, Bruce, MD, PhD, Wasfi, Yasmine, MD, PhD, Shen, Yaung-Kaung, PhD, Li, Shu, PhD, Kimball, Alexa B., MPH, MD

Volltext

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials von Reich, Kristian, Prof, Papp, Kim A, MD, Blauvelt, Andrew, MD, Tyring, Stephen K, Prof, Sinclair, Rodney, Prof, Thaçi, Diamant, Prof, Nograles, Kristine, MD, Mehta, Anish, BA, Cichanowitz, Nicole, MSJ, Li, Qing, PhD, Liu, Kenneth, PhD, La Rosa, Carmen, MD, Green, Stuart, MD, Kimball, Alexa B, Prof

Volltext

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis von Gordon, Kenneth B, Blauvelt, Andrew, Papp, Kim A, Langley, Richard G, Luger, Thomas, Ohtsuki, Mamitaro, Reich, Kristian, Amato, David, Ball, Susan G, Braun, Daniel K, Cameron, Gregory S, Erickson, Janelle, Konrad, Robert J, Muram, Talia M, Nickoloff, Brian J, Osuntokun, Olawale O, Secrest, Roberta J, Zhao, Fangyi, Mallbris, Lotus, Leonardi, Craig L

Volltext

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-lab... von Papp, Kim A., MD, PhD, Krueger, James G., MD, PhD, Feldman, Steven R., MD, PhD, Langley, Richard G., MD, Thaci, Diamant, MD, Torii, Hideshi, MD, PhD, Tyring, Stephen, MD, PhD, Wolk, Robert, MD, PhD, DSc, Gardner, Annie, MS, Mebus, Charles, PhD, Tan, Huaming, PhD, Luo, Yingchun, PhD, Gupta, Pankaj, PhD, Mallbris, Lotus, MD, PhD, Tatulych, Svitlana, MD

Volltext

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled p... von Armstrong, April W., Gooderham, Melinda, Warren, Richard B., Papp, Kim A., Strober, Bruce, Thaçi, Diamant, Morita, Akimichi, Szepietowski, Jacek C., Imafuku, Shinichi, Colston, Elizabeth, Throup, John, Kundu, Sudeep, Schoenfeld, Steve, Linaberry, Misti, Banerjee, Subhashis, Blauvelt, Andrew

Volltext

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-... von Gordon, Kenneth B, Strober, Bruce, Lebwohl, Mark, Augustin, Matthias, Blauvelt, Andrew, Poulin, Yves, Papp, Kim A, Sofen, Howard, Puig, Lluís, Foley, Peter, Ohtsuki, Mamitaro, Flack, Mary, Geng, Ziqian, Gu, Yihua, Valdes, Joaquin M, Thompson, Elizabeth H Z, Bachelez, Hervé

Volltext

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr ... von Strober, Bruce, Thaçi, Diamant, Sofen, Howard, Kircik, Leon, Gordon, Kenneth B., Foley, Peter, Rich, Phoebe, Paul, Carle, Bagel, Jerry, Colston, Elizabeth, Throup, John, Kundu, Sudeep, Sekaran, Chitra, Linaberry, Misti, Banerjee, Subhashis, Papp, Kim A.

Volltext

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa von Kimball, Alexa B, Okun, Martin M, Williams, David A, Gottlieb, Alice B, Papp, Kim A, Zouboulis, Christos C, Armstrong, April W, Kerdel, Francisco, Gold, Michael H, Forman, Seth B, Korman, Neil J, Giamarellos-Bourboulis, Evangelos J, Crowley, Jeffrey J, Lynde, Charles, Reguiai, Ziad, Prens, Errol-Prospero, Alwawi, Eihab, Mostafa, Nael M, Pinsky, Brett, Sundaram, Murali, Gu, Yihua, Carlson, Dawn M, Jemec, Gregor B.E

Volltext

Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics von Mease, Philip J., MD, Gladman, Dafna D., MD, Papp, Kim A., MD, PhD, Khraishi, Majed M., MD, Thaçi, Diamant, MD, Behrens, Frank, MD, Northington, Robert, PhD, Fuiman, Joanne, MS, Bananis, Eustratios, PhD, Boggs, Robert, PhD, Alvarez, Daniel, MD

Volltext

Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis von Papp, Kim, Gordon, Kenneth, Thaçi, Diamant, Morita, Akimichi, Gooderham, Melinda, Foley, Peter, Girgis, Ihab G, Kundu, Sudeep, Banerjee, Subhashis

Volltext

Bimekizumab versus Adalimumab in Plaque Psoriasis von Warren, Richard B, Blauvelt, Andrew, Bagel, Jerry, Papp, Kim A, Yamauchi, Paul, Armstrong, April, Langley, Richard G, Vanvoorden, Veerle, De Cuyper, Dirk, Cioffi, Christopher, Peterson, Luke, Cross, Nancy, Reich, Kristian

Volltext

Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis von Lebwohl, Mark G, Stein Gold, Linda, Strober, Bruce, Papp, Kim A, Armstrong, April W, Bagel, Jerry, Kircik, Leon, Ehst, Benjamin, Hong, H. Chih-ho, Soung, Jennifer, Fromowitz, Jeff, Guenthner, Scott, Piscitelli, Stephen C, Rubenstein, David S, Brown, Philip M, Tallman, Anna M, Bissonnette, Robert

Volltext

Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator... von Reich, Kristian, Papp, Kim A, Blauvelt, Andrew, Langley, Richard G, Armstrong, April, Warren, Richard B, Gordon, Kenneth B, Merola, Joseph F, Okubo, Yukari, Madden, Cynthia, Wang, Maggie, Cioffi, Christopher, Vanvoorden, Veerle, Lebwohl, Mark

Volltext

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis von Papp, Kim A, Blauvelt, Andrew, Bukhalo, Michael, Gooderham, Melinda, Krueger, James, Lacour, Jean-Philippe, Menter, Alan, Philipp, Sandra, Sofen, Howard, Tyring, Stephen, Berner, Beate R, Visvanathan, Sudha, Pamulapati, Chandrasena, Bennett, Nathan, Flack, Mary, Scholl, Paul, Padula, Steven J

Volltext

Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: Results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study von Kim, Brian S., Sun, Kang, Papp, Kim, Venturanza, May, Nasir, Adnan, Kuligowski, Michael E.

Volltext

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind,... von Guttman-Yassky, Emma, Teixeira, Henrique D, Simpson, Eric L, Papp, Kim A, Pangan, Aileen L, Blauvelt, Andrew, Thaçi, Diamant, Chu, Chia-Yu, Hong, H Chih-ho, Katoh, Norito, Paller, Amy S, Calimlim, Brian, Gu, Yihua, Hu, Xiaofei, Liu, Meng, Yang, Yang, Liu, John, Tenorio, Allan R, Chu, Alvina D, Irvine, Alan D

Volltext

Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-c... von Papp, Kim A., Merola, Joseph F., Gottlieb, Alice B., Griffiths, Christopher E.M., Cross, Nancy, Peterson, Luke, Cioffi, Christopher, Blauvelt, Andrew

Volltext